On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...
Beam’s medicine uses a technology known as base editing to activate a gene in stem cells collected from people with sickle ...
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...
Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...
Philadelphia Inquirer on MSN12h
Their son died after his first day of football practice at Bucknell. They want answers.It’s a rare condition triggered by exercise that is too intense in someone with the sickle cell trait, a sickle cell gene inherited from just one parent. Such exercise can cause the body’s red blood ...
Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...
Beam Therapeutics (BEAM) stock falls as patient dies after receiving the company's gene editing therapy.in an early-stage ...
CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...
CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...
Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...
Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...
Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback